Eton Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Eton Pharmaceuticals, Inc. on April 11, 2022. The filing reports a significant change in executive leadership effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on personnel changes and compensation arrangements.
Material Changes
- Appointment: James Gruber was appointed as Chief Financial Officer, Corporate Secretary, and Treasurer, effective April 11, 2022.
- Departure: Wilson Troutman retired from the same positions effective April 11, 2022.
- Transition: Mr. Troutman will remain with the company through May 31, 2022, to assist with the transition and is available for part-time consulting thereafter.
Compensation and Outlook
Mr. Gruber's compensation package includes:
- Base Salary: $350,000 annually.
- Incentive Bonus: Target amount of 40% of base salary, discretionary based on performance targets.
- Equity Grant: A one-time option to purchase 100,000 shares of common stock, vesting quarterly over four years.
The filing notes that the selection was not pursuant to any arrangement with other persons and confirms no family relationships between Mr. Gruber and existing directors or officers.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 100,000 share option granted to Mr. Gruber in the Company's equity incentive plan.
- Confirm the specific performance targets for the discretionary bonus component of Mr. Gruber's compensation.
- Review the transition plan details between Mr. Troutman and Mr. Gruber to ensure continuity of financial reporting.
- Check for any subsequent filings regarding the status of Mr. Troutman's consulting agreement post-May 31, 2022.